Valneva SE (VALN)
6.30
-0.01 (-0.16%)
At close: Apr 11, 2025, 3:59 PM
6.29
-0.16%
After-hours: Apr 11, 2025, 04:00 PM EDT
-0.16% (1D)
| Bid | 6 |
| Market Cap | 511.55M |
| Revenue (ttm) | 169.58M |
| Net Income (ttm) | -12.25M |
| EPS (ttm) | -0.17 |
| PE Ratio (ttm) | -37.06 |
| Forward PE | -8.24 |
| Analyst | Buy |
| Ask | 7.53 |
| Volume | 8,138 |
| Avg. Volume (20D) | 84,409 |
| Open | 6.22 |
| Previous Close | 6.31 |
| Day's Range | 5.99 - 6.30 |
| 52-Week Range | 3.62 - 9.50 |
| Beta | 1.29 |
About VALN
Valneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile tox...
Industry Biotechnology
Sector Healthcare
IPO Date May 5, 2021
Employees 713
Stock Exchange NASDAQ
Ticker Symbol VALN
Website https://valneva.com
Analyst Forecast
According to 2 analyst ratings, the average rating for VALN stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 153.97% from the latest price.
Stock ForecastsNext Earnings Release
Valneva SE is scheduled to release its earnings on May 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+3.63%
Valneva shares are trading higher after reaching a...
Unlock content with
Pro Subscription
1 month ago
+9.9%
Valneva shares are trading higher after the company announced a year-over-year increase in FY24 preliminary revenue results. Additionally, Valneva provided a FY25 outlook.
